Unknown

Dataset Information

0

Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?


ABSTRACT: India has a large share of the hepatitis C virus (HCV) burden of the world. Unsafe medical practices and blood transfusions are the leading modes of transmission of HCV in India. The commonest HCV genotype in India is genotype 3 followed by genotype 1. While directly acting antivirals (DAAs) agents have become available at reasonable rates in India, cost of therapy remains a major barrier for control of HCV in India. Generic DAAs have been proven to be cost-saving in prior studies. We examined data from various studies in India and elsewhere using generic DAAs, and evaluated whether they are equally efficacious as the branded drugs. Since the availability of generic DAAs in the Indian market, there is a lot of real life data as well as prospective studies in special patient populations such as hematological disorders (thalassemia and hemophilia), chronic kidney disease, hemodialysis patients, post liver and renal transplant patients on immunosuppression, intravenous drug users, confections and other high risk groups. Control of HCV infection in India requires multi pronged approach. There is a need to formulate a health educational curriculum targeting not only the high-risk population but also the general population regarding the transmission of HCV. Adopting the dual approach of treating the old cases (decreasing the reservoir pool of HCV) and decreasing the incidence of new ones would help curtail the disease and decrease liver related mortality. In this scenario, the role of efficacious low cost generic medications is essential.

SUBMITTER: Premkumar M 

PROVIDER: S-EPMC5620363 | biostudies-other | 2017 Sep

REPOSITORIES: biostudies-other

altmetric image

Publications

Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?

Premkumar Madhumita M   Grover Gagandeep S GS   Dhiman Radha K RK  

Journal of clinical and experimental hepatology 20170923 3


India has a large share of the hepatitis C virus (HCV) burden of the world. Unsafe medical practices and blood transfusions are the leading modes of transmission of HCV in India. The commonest HCV genotype in India is genotype 3 followed by genotype 1. While directly acting antivirals (DAAs) agents have become available at reasonable rates in India, cost of therapy remains a major barrier for control of HCV in India. Generic DAAs have been proven to be cost-saving in prior studies. We examined d  ...[more]

Similar Datasets

| S-EPMC10673679 | biostudies-literature
| S-EPMC9500682 | biostudies-literature
| S-EPMC3267478 | biostudies-literature
| S-EPMC11222407 | biostudies-literature
| S-EPMC10908238 | biostudies-literature
| S-EPMC5529495 | biostudies-literature
| S-EPMC5319496 | biostudies-literature
| S-EPMC7490961 | biostudies-literature
| S-EPMC9142352 | biostudies-literature
| S-EPMC6306198 | biostudies-literature